Past Meetings

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Garon, UCLA and Dr. Neal, Stanford on Novel therapies in Lung Cancer. Sponsored by AstraZeneca and Daiichi Sankyo.

View Details ►

This networking opportunity is designed to connect with peers, enjoy a wonderful lunch with a marina ocean view, and get to know your local Association, MOASC.

View Details ►

Recent FDA approvals in Multiple Myeloma, Prostate Cancer and Lung Cancer

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Lisberg, UCLA and Dr. Mansfield, Mayo Clinic on Antibody Drug Conjugates. Sponsored by AstraZeneca and Daiichi Sankyo.

View Details ►

Learn about cutting edge technologies and their optimal clinical application.

View Details ►

Virtually join your colleagues to learn about tools and resources to keep you successful.

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Sandhu, UC San Diego Health and Dr. Chen (Rad Onc), Scripps on the Treatment of Unresectable Stage 3 Disease. Sponsored by AstraZeneca.

View Details ►

Overview of Clinical Data for NERLYNX in Extended Adjuvant HER2+ Breast Cancer

View Details ►

Virtually join your colleagues to learn about tools and resources to keep you successful.

View Details ►

An Overview of Clinical Data for ENHERTU in HER2-Expressing Metastatic Breast Cancer-MD

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Forde, Johns Hopkins and Dr. Boys (CT Surgery), UCSD on New-adjuvant and Adjuvant therapy (targeted/immunotherapy). Sponsored by AstraZeneca.

View Details ►

ANCO and MOASC are pleased to host a course for oncologists, oncology nurses, and oncology practice managers composed of multidisciplinary presentations and discussions regarding health equity and oncology.

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Jang, Kaiser and Dr. Balmanoukian, The Angeles Clinic on Subsequent line therapy. Sponsored by AstraZeneca.

View Details ►

Discussion on the role biomarkers play in NSCLC including CEACAM5

View Details ►

We will discuss how AI-enabled technology can help your practice succeed in value-based reimbursement programs .

View Details ►

Covering timely updates in clinical practice, research & development, and technology & drug advancements in the field of medical oncology. Oncology experts will discuss innovations in the diagnosis and management of complex oncology issues.

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Garon, UCLA and Dr. Lashkari, Welness Oncology, MOASC Presidenton First line IO therapy in the metastatic setting. Sponsored by AstraZeneca.

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Goldman, UCLA and Dr. Bazhenova, UCSD on Post-ASCO Review. Sponsored by AstraZeneca.

View Details ►

CME certified, ABIM MOC-eligible live webinar

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Oxnard, Boston Medical Center and Dr. Neal, Stanford on the molecular diagnostics in NSCLC-liquid and tissue NGS – issues surrounding testing/interpretation. Sponsored by A

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Massarelli, City of Hope and Dr. Nagasaka, UCI on the Treatment of other targetable mutations (MET/RET/HER2). Sponsored by AstraZeneca.

View Details ►

Clinical Trials, Virtual Care, Special Programs to include Neo-Adjuvant & Adjuvant Trial Updates and Discussion.

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Mark M. Awad, MD, PhD, Harvard and Vamsidhar Velcheti, MD, NYU Langone Health on the Treatment of KRAS. Sponsored by Amgen and AstraZeneca.

View Details ►

Come Join Us!

View Details ►

In-person Board of Directors Meeting

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Ou, UCI and Dr. Reckamp, Cedars-Sinai on the Treatment of ALK/ROS NSCLC. Sponsored by AstraZeneca.

View Details ►

Come Join Us!

View Details ►

Moderated by Hatim Husain, MD, UC San Diego and discussants: Dr. Goldman, UCLA, and Dr. Riess, UC Davis on the Treatment of EGFR NSCLC (Classical Mutations). Sponsored in part by Janssen Oncology.

View Details ►